Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L.

Ann Intern Med. 2000 Sep 19;133(6):401-10.

PMID:
10975957
2.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
3.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
4.
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.

Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):284-92.

PMID:
15980687
7.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
8.

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART.

Nicastri E, Chiesi A, Angeletti C, Sarmati L, Palmisano L, Geraci A, Andreoni M, Vella S; Italian Antiretroviral Treatment Group (IATG)..

J Med Virol. 2005 Jun;76(2):153-60.

PMID:
15834865
9.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD..

PLoS One. 2006 Dec 20;1:e89.

10.
11.

Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.

Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.

AIDS. 2004 Oct 21;18(15):2029-38.

PMID:
15577624
12.
13.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
14.

Response to highly active antiretroviral therapy according to duration of HIV infection.

Pezzotti P, Pappagallo M, Phillips AN, Boros S, Valdarchi C, Sinicco A, Zaccarelli M, Rezza G; Italian Seroconversion Study..

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):473-9.

PMID:
11391168
15.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
16.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA.

AIDS. 2000 Jul 28;14(11):1545-52.

PMID:
10983641
17.

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

Ann Intern Med. 2001 Dec 4;135(11):954-64.

PMID:
11730396
18.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
19.

Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.

Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthé H, de Truchis P, Zucman D, Rouveix E, Saiag P.

AIDS. 2000 May 26;14(8):987-93.

PMID:
10853980
Items per page

Supplemental Content

Support Center